_www_larval_com_
Posted - 2 hours ago
$BRKR just shot 6% higher to 4% (~691Kv) moments ago, 05/17 options, follow for more volatility.
Jodah
Posted - 15 hours ago
$BRKR
Stock_Titan
Posted - 1 day ago
$BRKR Access Reminder for Bruker Investor Webinar on May 17, 2024
https://www.stocktitan.net/news/BRKR/access-reminder-for-bruker-investor-webinar-on-may-17-1v46mrkin5hj.html
uddin
Posted - 1 week ago
$NSTGQ $BRKR 11 billion dollars company bought out guys what you think they are not playing game ? PT double digits 🚀🔥💯💰🔜
Jodah
Posted - 1 week ago
$BRKR sinking ship
PimpinPEGY
Posted - 1 week ago
$NSTGQ I can’t be mad at Nanostrings as I believe they did everything they could to stay afloat. I will get satisfaction from knowing that Genomics screwed themselves in the end. How? While they were successful in putting Nanostring out of business, they now have to contend with a MUCH more powerful company ~> $BRKR <~as their competition. Good Job $TGX 🥳
DonCorleone77
Posted - 1 week ago
$BRKR $TXG Bruker says German court rules against 10x Genomics patent claim Bruker (BRKR) announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany by invalidating European Patent No. 2794928B1 in Germany. NanoString is now a Bruker business following Bruker's asset acquisition of the businesses of NanoString Technologies on May 6. The '928 Patent has been asserted by 10x Genomics (TXG) against NanoString in patent infringement cases in Germany and before the European Unified Patent Court involving NanoString's CosMx Spatial Molecular Imager products for RNA detection. The Federal Patent Court ruled that the German part of the '928 Patent is invalid. NanoString "will promptly ask the German Higher Regional Court of Munich to permanently lift the injunction impacting NanoString's CosMx products and the scientists who rely on them in Germany," the company added.
Stock_Titan
Posted - 1 week ago
$BRKR German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker
https://www.stocktitan.net/news/BRKR/german-federal-patent-court-invalidates-patent-asserted-by-10x-szwkoieuzlbg.html
Stock_Titan
Posted - 1 week ago
$BRKR Bruker Completes Asset Acquisition of NanoString Business
https://www.stocktitan.net/news/BRKR/bruker-completes-asset-acquisition-of-nano-string-gjjy72k517jf.html
SharePlanner
Posted - 1 week ago
$BRKR remains to be seen, whether support here will hold, but notable support nonetheless, that could be played with a close above the 200-day MA.
lecorb
Posted - 2 weeks ago
$BRKR Organic revenue growth of 5% to 7%, no change from prior guidance Constant exchange rate (CER) revenue growth of 12% to 14%, up 400 bps vs. prior guidance, and reflecting all closed acquisitions, including Chemspeed and ELITech Foreign currency translation headwind of -1%, vs. prior expectation of a +1% tailwind. Bruker now expects FY 2024 non-GAAP EPS of $2.79 to $2.84, up 8 cents from our prior guidance of $2.71 to $2.76, and excluding the estimated impact of the pending dilutive NanoString acquisition. Bruker's updated FY 2024 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of March 31, 2024.
lecorb
Posted - 2 weeks ago
$BRKR Bruker Updates 2024 Outlook: Now Sees Revenue Of $3.29B-$3.35B (Prior $3.23B-$3.29B) Vs. $3.282B Est.; Sees Adjusted EPS Of $2.79 To $2.84 (Prior $2.71-$2.76) Vs. $2.71 Est. 7:20 am ET May 2, 2024 (Benzinga) Fiscal Year 2024 Financial Outlook Bruker's FY 2024 updated guidance now includes the expected benefits of the Chemspeed acquisition closed in Q1 2024, and of the ELITech acquisition, which closed on April 30, 2024. Our updated FY 2024 guidance does not include the pending, EPS-dilutive NanoString acquisition, announced by Bruker on April 22, 2024, and expected to close in Q2-24. Bruker now expects FY 2024 revenues of $3.29 to $3.35 billion, up $60 million from our prior guidance of $3.23 to $3.29 billion. Bruker's updated FY 2024 revenue guidance implies 11% to 13% year-over-year reported revenue growth, up from our prior guidance of 9% to 11%, and including yoy contributions from: CONTINUE...
Jodah
Posted - 2 weeks ago
$BRKR -11%… good luck with your horrible acquisitions
50bps
Posted - 2 weeks ago
$BRKR 👀👀
epsguid
Posted - 2 weeks ago
$BRKR reported earnings of $0.53, consensus was $0.46 via @eWhispers #epsbeat http://eps.sh/d/brkr
Stock_Titan
Posted - 2 weeks ago
$BRKR Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
https://www.stocktitan.net/news/BRKR/bruker-completes-acquisition-of-molecular-diagnostics-innovator-eli-zp3z5cur1vz3.html
Stock_Titan
Posted - 04/26/24
$BRKR Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
https://www.stocktitan.net/news/BRKR/bruker-further-enhances-clinical-microbiology-amp-infection-8k50c80t2r21.html
Stock_Titan
Posted - 04/25/24
$BRKR Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast
https://www.stocktitan.net/news/BRKR/bruker-announces-date-and-time-of-first-quarter-2024-earnings-gcfxte9gt02g.html
tradingtwenty
Posted - 04/23/24
Top 5 oversold stocks that have trended in the past 24 hours: $BYON 18.01🔥 $PWSC 19.00 $CPRI 19.22 $CRNC 20.55 $BRKR 23.96 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past
Krzysiu
Posted - 04/22/24
$NSTGQ The PR from $BRKR caught more attention. I am confident the sale proceeds cover all outstanding debts & fees. Ran through the figures multiple times and have seen others formulate a similar conclusion. I can't think of a good enough reason why NSTG management would want to keep their existing securities trading OTC. I anticipate shareholder compensation for shares from the residual proceeds, that would result in significant gain even at current share price.
tradingtwenty
Posted - 04/22/24
Top 5 oversold stocks that have trended in the past 24 hours: $PLD 15.23🔥 $BYON 18.27 $PATH 21.87 $BRKR 22.67 $CTRN 23.12 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past
DonCorleone77
Posted - 04/22/24
$BRKR Bruker to acquire NanoString in $329.6M asset deal, sees accretion Bruker announced that it has entered into a definitive acquisition agreement with NanoString Technologies, headquartered in Seattle, Washington, a provider of solutions for spatial transcriptomics and gene expression analysis. Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString's business, including the nCounter, GeoMx, CosMx and AtoMx product lines, for approximately $392.6M in cash, and the assumption of certain liabilities. In 2023, NanoString generated revenues of approximately $168M. On April 19, the transaction was approved under a court-supervised Chapter 11 sale process pursuant to Section 363 of the U.S. Bankruptcy Code, and it is expected to close in the second quarter of 2024, subject to customary closing conditions. NanoString is a provider of life science tools for discovery and translational research with leading solutions for spatial transcriptomics and gene expression analysis. For over fifteen years, and with over 7,000 peer-reviewed publications, scientists and medical researchers have relied on NanoString's pioneering instruments to advance biological, translational and clinical disease research. Bruker expects to fund the acquisition with cash on hand and established debt instruments. Following the closing, the NanoString business will become part of the Bruker Spatial Biology business. Bruker is unable to provide guidance estimates for the NanoString business for the remainder of 2024, as its financial performance cannot yet be reliably estimated, given the disruption of the Chapter 11 reorganization, the previous European Unified Patent Court's injunction on CosMx sales, and the uncertainties of various U.S. and European IP and antitrust litigation proceedings against an unusually aggressive, larger spatial and single-cell biology competitor. As a preliminary estimate, for the remainder of 2024, the transaction is expected to be dilutive to non-GAAP EPS by 15c to 20c. By 2026, Bruker expects the NanoString business to have rebounded and to be near break-even with resumed revenue growth and margin improvements, also taking advantage of deal synergies, as Bruker is not acquiring NanoString's public company overhead in this asset deal.
OpenOutcrier
Posted - 04/22/24
$BRKR (+0.3% pre) Bruker to Acquire the NanoString Business in an Asset Deal - BW https://ooc.bz/l/30956
Stock_Titan
Posted - 04/22/24
$BRKR Bruker to Acquire the NanoString Business in an Asset Deal
https://www.stocktitan.net/news/BRKR/bruker-to-acquire-the-nano-string-business-in-an-asset-twxghxyd4cfz.html
DA87
Posted - 04/20/24
On 3/10 $NSTGQ issued a PR stating Patient Square Capital will take them private. What makes us think the $BRKR deal does not include the same?
Jodah
Posted - 04/18/24
$BRKR many bad acquisitions last one being chapter 11 company Nanostring. Are these guys nuts? Do they have any money left?
putih
Posted - 4 weeks ago
$NSTGQ Based on after hours action, the market reckons $BRKR has only increased in value by $145M. The management clearly knows otherwise, so I'm guessing there will be a price jump tomorrow morning.
Stock_Titan
Posted - 1 month ago
$BRKR Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
https://www.stocktitan.net/news/BRKR/bruker-advances-magnet-technology-for-broader-adoption-of-nmr-in-fphsibyo9x59.html
